Cancer research headlines: check the evidence and access
The September 14 briefing looks at lung cancer trial reports and the questions a headline response rate cannot answer.
Three things to know
Reports from TAISHAN-302 and HARMONi-2 concern different drugs, patient groups and comparators. Results from one study or subgroup should not be treated as a prediction for every patient.
The early QLC5508 combination results involved only 20 patients whose response could be evaluated. The briefing notes that mature response-duration and survival results were still missing.
Acceptance of a regulatory filing is not approval. The source did not establish an international-patient pathway or confirmed price; research progress alone does not make treatment bookable.
This is a dated video briefing. Reports and availability may have changed since it was recorded; confirm current details before making plans.